These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Temsirolimus: a safety and efficacy review. Bukowski RM Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825 [TBL] [Abstract][Full Text] [Related]
3. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. Stenner-Liewen F; Grünwald V; Greil R; Porta C Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788 [TBL] [Abstract][Full Text] [Related]
4. Temsirolimus in renal cell carcinoma. Otto T; Eimer C; Gerullis H Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905 [TBL] [Abstract][Full Text] [Related]
5. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. Armstrong AJ; George DJ; Halabi S J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270 [TBL] [Abstract][Full Text] [Related]
6. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. Radulovic S; Bjelogrlic SK J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273 [TBL] [Abstract][Full Text] [Related]
7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Chan HY; Grossman AB; Bukowski RM Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346 [TBL] [Abstract][Full Text] [Related]
8. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Malizzia LJ; Hsu A Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330 [TBL] [Abstract][Full Text] [Related]
9. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966 [TBL] [Abstract][Full Text] [Related]
10. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578 [TBL] [Abstract][Full Text] [Related]
11. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. Danesi R; Boni JP; Ravaud A Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Figlin RA Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393 [TBL] [Abstract][Full Text] [Related]